Boulton D W, Fawcett J P
School of Pharmacy, University of Otago, Dunedin, New Zealand.
J Chromatogr B Biomed Appl. 1995 Oct 6;672(1):103-9. doi: 10.1016/0378-4347(95)00210-a.
Enantiomers of salbutamol were directly separated (Rs = 1.16) and quantitated at therapeutic concentrations after solid-phase extraction from human plasma and urine by normal-phase high-performance liquid chromatography on a chiral column with fluorescence detection. The assay was linear for each enantiomer between 1.25 and 500 ng ml-1 and had a minimum limit of detection of 250 pg ml-1. A 3-ml plasma or 1-ml urine sample was required for quantitation at therapeutic doses. Inter-day variation was 5.0% for S-(+)- and 6.5% for R-(-)-salbutamol. The assay was used to compare enantioselective disposition after single doses of racemate by the intravenous, oral and rectal routes.
通过在具有荧光检测的手性柱上进行正相高效液相色谱法,从人血浆和尿液中固相萃取后,直接分离(Rs = 1.16)并定量测定沙丁胺醇的对映体在治疗浓度下的含量。该测定法对每种对映体在1.25至500 ng ml-1之间呈线性,最低检测限为250 pg ml-1。在治疗剂量下进行定量需要3 ml血浆或1 ml尿液样本。S-(+)-沙丁胺醇的日间变化为5.0%,R-(-)-沙丁胺醇的日间变化为6.5%。该测定法用于比较通过静脉内、口服和直肠途径单次给予消旋体后对映体选择性处置情况。